The transaction is sourced from an SEC EDGAR Form 8-K filing published on October 1, 2025. Based on the facts provided, the deal's status is pending regulatory approval.
On the financial advisory side, J.P. Morgan Securities served as exclusive financial advisor to Iodine, the target, and is identified as the lead advisor on that side. Barclays served as exclusive financial advisor to Waystar, the acquirer, and is likewise identified as the lead advisor for the acquirer. Both firms are described as acting in an exclusive capacity for their respective clients.
On the legal side, Weil, Gotshal & Manges LLP and Queen Saenz + Schultz PLLC both served as legal advisors to Iodine, the target, indicating two legal advisors on that side of the transaction. Simpson Thacher & Bartlett LLP served as legal advisor to Waystar, the acquirer.
Beyond confirming that this is an acquisition in a closing phase, no further detail on the specific terms of consideration, such as a purchase price or payment structure, is included in the facts available.
A number of elements of this deal are not disclosed in the available material. The deal value is explicitly noted as not stated in the source document, and no detail on the structure of consideration is provided. While the subtype description notes the deal is in a closing phase, no specific closing date is given, and no detail on required regulatory approvals is included.